Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 9/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165149 | 0.87 | PDE4A (0.48) | PDE4APDE4D | |
| SCHEMBL10165203 | 0.86 | PDE4D (0.60) | PDE4APDE4D | |
| SCHEMBL7925725 | 0.76 | PDE4A (0.49) | PDE4APDE4D | |
| SCHEMBL17571377 | 0.75 | PDE4A (0.60) | PDE4APDE4DPDE10A | |
| SCHEMBL17571398 | 0.73 | PDE4D (0.48) | PDE4APDE4D | |
| SCHEMBL15060189 | 0.73 | PDE4D (0.59) | PDE4APDE4D | |
| SCHEMBL508221 | 0.73 | PDE4D (0.59) | PDE4APDE4D | |
| SCHEMBL3469402 | 0.72 | PDE4A (0.58) | PDE4APDE4D | |
| SCHEMBL15071014 | 0.72 | PDE4D (0.56) | PDE4APDE4D | |
| SCHEMBL15060224 | 0.72 | PDE4D (0.60) | PDE4APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952162-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2015-02-10 | — | — | US | disclosed |
| US-20120028974-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028974-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | PDE4A, PDE4B, PDE5A | PDE4A 1/4885PDE4D 5/4885PDE10A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.